Prakash Radhakrishnan
University of Nebraska Medical Center
H-index: 23
North America-United States
Top articles of Prakash Radhakrishnan
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
Journal of Nuclear Medicine
2024/4/1
Prakash Radhakrishnan
H-Index: 16
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9. 6
Molecular Cancer Therapeutics
2024/2/23
Benjamin Swanson
H-Index: 3
Prakash Radhakrishnan
H-Index: 16
MUC16 monoclonal antibody and uses thereof
2023/10/3
Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer
2023/3/29
Prakash Radhakrishnan
H-Index: 16
Michael Bouvet
H-Index: 47
The (Sialyl) Tn antigen: Contributions to immunosuppression in gastrointestinal cancers
2023/1/6
Prakash Radhakrishnan
H-Index: 16
Tianming Zhang1, Wenjun Li1, Danbei Diwu1, Lijun Chen1, Xi Chen2, 3 and Hong Wang1
2023
Prakash Radhakrishnan
H-Index: 16
Hong Wang
H-Index: 8
169 Immunotherapeutic potential of the humanized anti-MUC16 antibody AR9. 6 against PDAC
2022/11/1
Cory Brooks
H-Index: 11
Prakash Radhakrishnan
H-Index: 16
Truncated O-Glycan-Bearing MUC16 enhances pancreatic cancer cells aggressiveness via α4β1 integrin complexes and FAK signaling
International journal of molecular sciences
2022/5/13
Divya Thomas Chemparathy
H-Index: 8
Prakash Radhakrishnan
H-Index: 16
Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth
Proceedings of the National Academy of Sciences
2022/5/3
Structure of a Therapeutic Antibody in Complex with MUC16 Reveals a Conformational Epitope Influenced by Antigen Glycosylation
FASEB journal: official publication of the Federation of American Societies for Experimental Biology
2022/5
David Goodlett
H-Index: 50
Prakash Radhakrishnan
H-Index: 16
Insect cell expression and purification of recombinant SARS‐COV‐2 spike proteins that demonstrate ACE2 binding
Protein Science
2022/5
Prakash Radhakrishnan
H-Index: 16
ImmunoPET of ovarian and pancreatic cancer with AR9. 6, a novel MUC16-targeted therapeutic antibody
Clinical Cancer Research
2022/3/1
Prakash Radhakrishnan
H-Index: 16
Targeting Oxidative Stress Specific NRF2 In Pancreatic Cancer Stem Cells
2022/2/19
Prakash Radhakrishnan
H-Index: 16
Effect of MUC16 Blockade using the Humanized AR9. 6 Antibody in Patient Derived Organoid Models of PDAC
2022
Prakash Radhakrishnan
H-Index: 16
IgE-based therapeutic combination enhances antitumor response in preclinical models of pancreatic cancer
Molecular cancer therapeutics
2021/12/1
Ying Huang
H-Index: 10
Prakash Radhakrishnan
H-Index: 16
Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy
European journal of medicinal chemistry
2021/10/15
Sarbjit Singh
H-Index: 2
Jayapal Reddy Mallareddy
H-Index: 6
Sandeep Rana
H-Index: 3
Prakash Radhakrishnan
H-Index: 16
Mutant K-Ras Mediated Oxidative Stress in Pancreatic Cancer
2021/9/1
Prakash Radhakrishnan
H-Index: 16
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans
Cancer letters
2021/4/10
Hans H Wandall
H-Index: 34
Prakash Radhakrishnan
H-Index: 16
Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer
Molecular Therapy
2021/4/7
Xiang Liu
H-Index: 1
Thomas Caffrey
H-Index: 14
Benjamin Swanson
H-Index: 3
Hans H Wandall
H-Index: 34
Fang Yu
H-Index: 15
Prakash Radhakrishnan
H-Index: 16
Inhibition of the receptor for advanced glycation End products enhances the cytotoxic effect of gemcitabine in murine pancreatic tumors
Biomolecules
2021/4/1
Swetha Thiyagarajan
H-Index: 1
Prakash Radhakrishnan
H-Index: 16
